Nimvastid 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0024 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/01/2024 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
N/0023 
Minor change in labelling or package leaflet not 
26/01/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0022 
B.II.b.5.z - Change to in-process tests or limits 
11/07/2022 
n/a 
applied during the manufacture of the finished 
product - Other variation 
IB/0021 
C.I.z - Changes (Safety/Efficacy) of Human and 
07/02/2022 
03/02/2023 
SmPC, Annex 
To amend SmPC section 2 for the orodispersible to 
Veterinary Medicinal Products - Other variation 
II, Labelling 
essentially align with the wording given in the excipient 
and PL 
guidance for Sorbitol (E420). The package leaflet has been 
updated accordingly. 
The marketing authorisation holder took the opportunity to 
align the PI to the latest QRD template (version 10.2). This 
includes merging the SmPCs for hard capsules and 
orodispersible tables respectively. Also the contact details 
of the local representatives in Cyprus, Greece, Ireland, 
Iceland and United Kingdom (Northern Ireland). 
IA/0020 
B.II.b.3.a - Change in the manufacturing process of 
06/04/2021 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IA/0019 
B.II.b.4.a - Change in the batch size (including batch 
25/03/2021 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IA/0018/G 
This was an application for a group of variations. 
12/11/2020 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
IA/0017 
B.II.b.4.b - Change in the batch size (including batch 
30/01/2020 
n/a 
size ranges) of the finished product - Downscaling 
down to 10-fold 
N/0016 
Minor change in labelling or package leaflet not 
18/01/2018 
03/02/2023 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IB/0014 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
18/12/2015 
05/09/2016 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/12/2015 
05/09/2016 
SmPC, Annex 
generic/hybrid/biosimilar products following 
II and PL 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
18/08/2015 
05/09/2016 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Labelling and 
PL 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
R/0012 
Renewal of the marketing authorisation. 
21/11/2013 
16/01/2014 
SmPC, Annex 
Based on the review of the cumulative quality, efficacy and 
II, Labelling 
safety data from clinical trials and post-marketing studies 
and PL 
conducted with the reference medicinal product Exelon as 
well as from spontaneous reports and the scientific 
literature, the CHMP concluded that there were no changes 
to the known benefits and safety concerns associated with 
Nimvastid when used in the approved indications. The 
CHMP therefore concluded that the benefit/risk balance of 
Nimvastid remained favourable and recommended the 
renewal of the marketing authorisation with unlimited 
validity. 
IA/0011 
B.II.d.1.a - Change in the specification parameters 
15/07/2013 
n/a 
and/or limits of the finished product - Tightening of 
specification limits 
IB/0010 
C.I.2.a - Change in the SPC, Labelling or PL of a 
27/06/2012 
29/10/2012 
SmPC and PL 
Following the procedure for the originator product Exelon 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
EMEA/H/C/xxxx/WS/0132 Section 4.8 of the SmPC was 
updated to reflect the safety findings of the open-label 
safety study in patients with Parkinson’s disease dementia. 
Additionally, sections 4.3 and 4.4 were updated with 
information on skin application site reactions and skin 
hypersensitivity, recommendations on formulation 
switching and treatment discontinuation.  
The Package Leaflet was updated in accordance. Minor 
editorial changes were introduced throughout the Product 
Information.  
Additionally local representatives were updated. 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
IB/0009 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
05/06/2012 
29/10/2012 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
N/0008 
The Marketing Authorisation Holder (MAH) took the 
14/11/2011 
26/03/2012 
PL 
The Marketing Authorisation Holder (MAH) took the 
opportunity to update details of local representatives 
in Annex IIIB. Furthermore, minor corrections were 
made in Annex IIIA of Romanian PI and in Annex 
IIIB of Slovakian PI. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
opportunity to update details of local representatives in 
Annex IIIB. Furthermore, minor corrections were made in 
Annex IIIA of Romanian PI and in Annex IIIB of Slovakian 
PI. 
IB/0007/G 
This was an application for a group of variations. 
31/08/2011 
n/a 
SmPC and PL 
Update sections 4.3 and 4.4 of Nimvastid SmPC to change 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
the contraindication for patients with severe hepatic 
impairment into a warning. Section 4.4 of the SmPC is also 
revised to reflect that patients with clinically significant 
renal or hepatic impairment might experience more 
product - Implementation of change(s) for which NO 
adverse reactions. Section 4.2 is amended accordingly. In 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
addition, minor linguistic amendments have been 
introduced in the SmPC. 
The Package Leaflet of has been revised based on the 
results of a user testing of the reference product.  
In addition, section 4.8 of the SmPC has been amended to 
include new adverse reactions: dehydration, hepatitis, 
aggression, restlessness, sick sinus syndromes and anxiety.  
The whole section 4.8 has been revised according to the 
current MedDRA terminology. 
Furthermore, Section 4.4 of the SmPC has also been 
amended to include that gastrointestinal disorders may 
occur when in patients treated with rivastigmine and to 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
IB/0006 
Updated information on skin reactions has been 
21/06/2010 
n/a 
SmPC and PL 
include a warning for patients with low body weight. 
The Package Leaflet has been amended to reflect those 
changes, and the local representative section has also been 
updated. 
included in section 4.8 of the SPC and the 
corresponding section 4 of the Package Leaflet. 
In addition, minor amendments have been made 
throughout the Annexes and the Product information 
has been brought in line with current QRD 
requirements.  
This followed a wider update to the Product 
information of Exelon (the reference medicinal 
product) which included updates of other 
formulations (i.e. patches) via procedure 
EMEA/H/C/000169/II/0055. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IA/0005 
IA_41_a_01_Change in pack size - change in no. of 
20/07/2009 
20/07/2009 
SmPC, 
units within range of appr. pack size 
Labelling and 
PL 
IA/0004 
IA_41_a_01_Change in pack size - change in no. of 
20/07/2009 
20/07/2009 
SmPC, 
units within range of appr. pack size 
Labelling and 
PL 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0003 
IA_41_a_01_Change in pack size - change in no. of 
20/07/2009 
20/07/2009 
SmPC, 
units within range of appr. pack size 
Labelling and 
PL 
IA/0002 
IA_41_a_01_Change in pack size - change in no. of 
20/07/2009 
20/07/2009 
SmPC, 
units within range of appr. pack size 
Labelling and 
PL 
IA/0001 
IA_35_a_Change in weight of coating/capsule shells 
17/06/2009 
n/a 
- immediate release pharm. forms 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
